Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Participants With Rheumatoid Arthritis

NCT07895524 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07895524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Participants With Rheumatoid Arthritis
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 23, 2026
Completion date
November 28, 2028
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis

Arms

As registered; 3 arms.

  • Period 1: MK-8690 ExperimentalMK-8690, Methotrexate (MTX)

    Participant will receive MK-8690 subcutaneous (SC) for 12 weeks

  • Period 1: Placebo Placebo comparatorMethotrexate (MTX), Placebo

    Participant will receive placebo SC for 12 weeks

  • Extension Period ExperimentalMK-8690, Methotrexate (MTX)

    After completing Period 1 participants will receive MK-8690 SC for 40 weeks.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Percentage of Participants Achieving American College of Rheumatology 50% Response Criteria (ACR50) at Week 12 Week 12

    ACR response is a well-established composite measure used in clinical trials to evaluate clinical response in rheumatoid arthritis (RA). ACR50 response is defined as 50% or greater improvement in tender joint count (TJC) based on 68 joints, swollen joint count (SJC) based on 66 joints, and ≥3 of the 5 remaining components of Health Assessment Questionnaire-Disability Index (HAQ-DI), Physician Global Assessment of Disease Activity (PGA), Patient Global Assessment of Disease Activity (PtGA), Patient Assessment of Pain Severity, and high-sensitivity C-reactive protein (hsCRP). ACR50 is an accepted measure by the FDA to demonstrate reduction in RA disease activity and is defined as the proportion of participants achieving 50% improvement in the composite measure. The percentage of participants achieving ACR50 at Week 12 will be presented.

Lead sponsor's other trials

Merck Sharp & Dohme LLC, most recent start first.

Similar trials

Same condition (Arthritis, Rheumatoid) and phase, most recent start first.